News Summary
Oncocyte Corp. has announced its rebranding as Insight Molecular Diagnostics Inc. and is relocating its headquarters to Nashville, Tennessee. The company aims to expand its focus from oncology to transplant medicine. Beginning June 18, 2025, the company’s shares will be traded under the new Nasdaq ticker symbol “IMDX.” The rebranding includes a new product line for transplant diagnostics and a commitment to enhance testing access for kidney transplant patients.
Nashville – Oncocyte Corp. has officially announced its rebranding to Insight Molecular Diagnostics Inc. (iMDx) and is relocating its headquarters from Irvine, California, to Nashville, Tennessee. This transition marks a significant shift in the company’s focus, aiming to expand beyond oncology and into the realm of transplant medicine. The stock for the rebranded company will begin trading under the new Nasdaq ticker symbol “IMDX” on June 18, 2025.
The new initiatives highlighted by iMDx represent a strategic pivot that emphasizes enhancing the diagnostic tools available to doctors, laboratory technicians, and researchers, ultimately aiming to improve patient care. The decision to move the headquarters to Nashville is bolstered by the city’s reputation as a burgeoning hub for healthcare innovation, which is home to the company’s CLIA-certified laboratory.
Details of the Transition
Key elements of this rebranding and relocation include a renewed focus on diagnostic and molecular testing for various medical fields, particularly in transplant medicine. The company plans to unify its transplant diagnostics under the GraftAssure brand, retiring the formerly used VitaGraft name. This change reflects a comprehensive approach to providing advanced diagnostics specifically tailored for transplant patients, an area recognized for significant growth potential.
The GraftAssure product line will feature:
- GraftAssureCore: A lab-developed test currently reimbursed by CMS in Nashville.
- GraftAssureIQ: A Research Use Only kit designed for non-clinical applications.
- GraftAssureDx: An in vitro diagnostic kit under development and intended for clinical decision-making, which is planned for submission to the FDA.
In addition, iMDx aims to develop a molecular diagnostic kit that enhances testing access for kidney transplant patients. The target market for transplant rejection testing is estimated at $1 billion, representing a substantial opportunity for the company as it moves forward.
Background and Future Outlook
The rebranding to Insight Molecular Diagnostics leverages existing rights to the name Insight Genetics, which iMDx acquired in 2020. The company will continue to operate its laboratory and research center in Göttingen, Germany, while establishing its new headquarters in Nashville.
According to Andrea James, the CFO of iMDx, the transitions underway symbolize the beginning of a value-creation journey that is expected to enhance operational efficiency and market presence across various medical fields. As the healthcare landscape continues to evolve, iMDx is committed to pursuing innovations and partnerships that align with its operational strategy.
Nashville’s increasing concentration of healthcare talent and innovation resources stands to benefit iMDx significantly as it transitions into these new phases. The new iMDx logo proudly displays DNA banding patterns, embodying the company’s commitment to a healthcare provider-centric philosophy focused on delivering advanced diagnostic solutions.
Overall, the recent changes position iMDx to take significant strides in the market, enhancing its offerings to meet a broader range of medical needs while also aiming for greater operational efficiencies.
Deeper Dive: News & Info About This Topic
HERE Resources
Additional Resources
- Orange County Business Journal: Oncocyte Exits Irvine, Rebrands as Insight Molecular Diagnostics
- MarketScreener: Oncocyte Changes Name to Insight Molecular Diagnostics
- TipRanks: Oncocyte Changes Name to Insight Molecular Diagnostics
- Wikipedia: DNA
- Google Search: Oncocyte Insight Molecular Diagnostics
Author: STAFF HERE COSTA MESA
The Costa Mesa Staff Writer represents the experienced team at HERECostaMesa.com, your go-to source for actionable local news and information in Costa Mesa, Orange County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as the OC Fair, performances at the Pacific Amphitheatre, and community gatherings at The LAB Anti-Mall. Our coverage extends to key organizations like the Costa Mesa Chamber of Commerce and Visit Costa Mesa, plus leading businesses in retail, entertainment, and innovation that shape the local economy. As part of the broader HERE network, including HEREAnaheim.com, HERESantaAna.com, HEREHuntingtonBeach.com, and HERELosAngeles.com, we provide comprehensive, credible insights into Southern California's dynamic landscape.
